StocksK › KKPNF

Koninklijke KPN N.V. (KKPNF) — Earnings Call X-Ray

Our AI read all 15 of KKPNF's earnings calls (2018–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.

Latest Call Grade
🔒
Q2 2025 · sign up to see
Previous Call Grade
B+
Q1 2025
Expected Move
🔒
next 45 days · members
Calls Analyzed
15
2018–2025
Avg Candor
7.1/9
evasion 2.3/9
High CandorSkeptic ReassuredCritic AmmunitionRaising PricesMargins ExpandingBacklog GrowingCutting HeadcountCFO Dominates

Call-by-call analysis

🔒 Q2 2025 earnings call 2025-07-23 NEWEST

Guidance: ■■■■■Demand: ■■■■■■ Margins: ■■■■Backlog: ■■■■ ■ analysts, ■■ questionsexpected move ±■■%
Candor /9
Specificity /9
Evasion /9
Stress /9

Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.

🔒 The Q2 2025 call grade is ready
The full 37-point AI read of KKPNF's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock

B+ Q1 2025 earnings call 2025-04-24 move ±9.5%

Management held guidance steady against steady demand and expanding margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: stableMargins: expandingBacklog: growingPricing: raisingHeadcount: cuttingCapex: flat 10 analysts · 21 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsCFO dominatesDirection beats results
Candor 8/9
Specificity 8/9
Evasion 1/9
Confidence 7/9
Uncertainty 4/9
Promotion 2/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B+ Q1 2024 earnings call 2024-04-25 move ±7.2%

Management raised guidance against steady demand and expanding margins. The delivery was unusually candid, rich in specifics.

Guidance: raisedDemand: stableMargins: expandingPricing: raisingHeadcount: cuttingCapex: flat 9 analysts · 19 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 4/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B Q3 2023 earnings call 2023-10-25 move ±6.1%

Management held guidance steady against steady demand. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: stableMargins: stablePricing: raisingCapex: increasing 7 analysts · 16 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsedCFO dominates
Candor 7/9
Specificity 8/9
Evasion 1/9
Confidence 7/9
Uncertainty 3/9
Promotion 4/9
Stress 2/9
Complexity 5/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

B Q2 2023 earnings call 2023-07-24 move ±6%

Management held guidance steady against accelerating demand. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: acceleratingMargins: stableBacklog: growingPricing: raisingHeadcount: cuttingCapex: increasing 9 analysts · 19 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth⚑ Reads rehearsed
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 8/9
Uncertainty 3/9
Promotion 4/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

C+ Q1 2023 earnings call 2023-04-26 move ±8.7%

Management held guidance steady against mixed demand signals and contracting margins. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: mixedMargins: contractingBacklog: growingPricing: raisingCapex: increasing 8 analysts · 16 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growthHidden segment
Candor 7/9
Specificity 7/9
Evasion 2/9
Confidence 7/9
Uncertainty 4/9
Promotion 3/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
YES Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

C+ Q3 2022 earnings call 2022-10-27 move ±9.8%

Management held guidance steady against steady demand. The delivery was unusually candid, rich in specifics.

Guidance: maintainedDemand: stableMargins: stablePricing: raisingHeadcount: cuttingCapex: flat 11 analysts · 23 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubtsCFO dominates
Candor 7/9
Specificity 8/9
Evasion 3/9
Confidence 7/9
Uncertainty 5/9
Promotion 4/9
Stress 3/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?

B+ Q2 2022 earnings call 2022-07-28 move ±6.8%

Management raised guidance against mixed demand signals. The delivery was unusually candid, rich in specifics.

Guidance: raisedDemand: mixedMargins: stablePricing: raisingHeadcount: cuttingCapex: flat 10 analysts · 22 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsedHidden segment
Candor 7/9
Specificity 8/9
Evasion 2/9
Confidence 7/9
Uncertainty 3/9
Promotion 5/9
Stress 2/9
Complexity 4/9
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
YES Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?

Earlier calls

CallDateGradeGuidanceDemandMarginsCandorEvasion
Q4 2021 2022-01-31 B maintainedstableexpanding 7/9 2/9
Q3 2021 2021-10-26 B maintainedacceleratingexpanding 7/9 2/9
Q2 2020 2020-07-27 C+ maintainedmixedstable 8/9 3/9
Q3 2019 2019-10-25 C+ maintainedmixedexpanding 7/9 3/9
Q2 2019 2019-07-27 B+ raisedmixedexpanding 7/9 3/9
Q1 2019 2019-04-29 C+ maintainedmixedstable 7/9 3/9
Q3 2018 2018-10-24 C maintainedmixedstable 6/9 4/9

How to read this page

The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.

Companies with similar call quality

AAN · The Aaron's Company, IncAAWW · Atlas Air Worldwide HoldABAX · ABAXISABCB · Ameris BancorpABM · ABM Industries IncorporaACBI · Atlantic Capital Bancsha

KKOYF   All “K” companies    KKR

Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.